StudyRareStudyRare

WAGR Syndrome (11p13 deletion)

Log in to star

Last updated Nov 3, 2026

Log in to add personal notes on this page.

A newborn is noted to have aniridia. Given this finding, the provider orders a CMA which shows an 11p13 deletion. The care team initiates Wilms tumor surveillance.

  • AD, typically de novo; contiguous gene deletion at 11p13
  • Always includes WT1 (Wilms tumor protein, a transcription factor and tumor suppressor) and PAX6 (aniridia); haploinsufficiency of each

Each letter of WAGR traces to haploinsufficiency of a gene inside the deletion:

  • WT1 encodes a transcription factor that directs cell differentiation in the kidney, urinary tract, and gonadal progenitor cells, and it also acts as a tumor suppressor. Half the normal dose explains the Wilms tumor risk (about 50% overall, mostly before age 5) and the genital anomalies, which resemble those of WT1 disorder.
  • PAX6 encodes a paired box DNA-binding protein that controls organogenesis; its loss gives the aniridia and the other features of PAX6 aniridia syndrome.
  • BDNF, when the deletion includes it, is associated with hyperphagia and childhood-onset obesity; obesity is less common when BDNF is spared.
  • ALX4 and EXT2, when a larger deletion reaches them, add Potocki-Shaffer syndrome: enlarged parietal foramina and multiple osteochondromas.

The genes behind the neurodevelopmental range are not established. ELP4, PRRG4, and SLC1A2 are candidates, but small numbers prevent firm conclusions. Low-level mosaicism for the deletion has been reported and can be missed by a standard microarray, so a strong clinical suspicion warrants a test that accounts for it.

WAGR

  • Wilms tumor risk (~50%; highest risk under age 8)
  • Aniridia (absence of iris)
  • Genitourinary anomalies (cryptorchidism, hypospadias)
  • Range of developmental delays (as with most microdeletion syndromes)
  • Chromosomal microarray (CMA) is the test of choice when WAGR is suspected, because the cause is a deletion that an exome without copy-number calling can miss; it defines the extent of the 11p13 deletion, including involvement of WT1 and PAX6
  • Isolated aniridia warrants PAX6 and 11p13 evaluation; finding a contiguous WT1 deletion establishes WAGR and triggers Wilms tumor surveillance
  • WT1 involvement also raises the risk of nephropathy, so confirm whether WT1 is within the deleted segment
  • Wilms tumor surveillance: renal ultrasound every 3 months until age 8
  • Ophthalmologic evaluation

Reference Links